We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+31.58%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$250M
AUM Growth
+$80.2M
Cap. Flow
+$54.1M
Cap. Flow %
21.67%
Top 10 Hldgs %
36.89%
Holding
128
New
62
Increased
6
Reduced
21
Closed
36

Top Buys

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$6.46M
2
HOLX
Hologic
HOLX
+$3.37M
3
SYNH
Syneos Health, Inc. Class A Common Stock
SYNH
+$2.9M
4
STAA icon
STAAR Surgical
STAA
+$2.34M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$2.33M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$4.14M
2
ALXN
Alexion Pharmaceuticals
ALXN
+$4.09M
3
ABT icon
Abbott
ABT
+$3.63M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$3.54M
5
GMED icon
Globus Medical
GMED
+$3.52M

Sector Composition

Rank Sector Weight
1 Healthcare 37.06%
2 Industrials 1.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CSII
51
CALL
DELISTED
Cardiovascular Systems, Inc.
CSII
$1.88M 0.75%
+58,000
New +$1.6M
MRK icon
52
Merck
MRK
$323B
$1.82M 0.73%
31,440
-73,360
-70% -$4.14M
ZGNX
53
PUT
DELISTED
Zogenix, Inc.
ZGNX
$1.6M 0.64%
+36,100
New +$1.49M
CORT icon
54
PUT
Corcept Therapeutics
CORT
$12.3B
$1.57M 0.63%
+100,200
New +$1.74M
AXDX
55
CALL
DELISTED
Accelerate Diagnostics
AXDX
$1.56M 0.63%
+7,000
New +$1.57M
RIGL icon
56
Rigel Pharmaceuticals
RIGL
$778M
$1.56M 0.62%
55,000
-3,456
-6% -$123K
TECX
57
Tectonic Therapeutic
TECX
$639M
$1.5M 0.6%
+4,375
New +$1.58M
ADMA icon
58
ADMA Biologics
ADMA
$2.18B
$1.47M 0.59%
+325,000
New +$1.62M
VRAY
59
CALL
DELISTED
ViewRay, Inc.
VRAY
$1.38M 0.55%
+200,000
New +$1.45M
CHRS icon
60
PUT
Coherus Oncology
CHRS
$192M
$1.36M 0.55%
+97,500
New +$1.4M
OBSV
61
DELISTED
ObsEva SA Ordinary Shares
OBSV
$1.36M 0.55%
+90,000
New +$1.2M
NVTR
62
DELISTED
Nuvectra Corporation Common Stock
NVTR
$1.33M 0.53%
65,000
-47,500
-42% -$801K
COLL icon
63
Collegium Pharmaceutical
COLL
$882M
$1.25M 0.5%
+52,219
New +$1.28M
ALXN
64
DELISTED
Alexion Pharmaceuticals
ALXN
$1.24M 0.5%
10,000
-35,000
-78% -$4.09M
IMMU
65
DELISTED
Immunomedics Inc
IMMU
$1.19M 0.48%
+50,400
New +$1.01M
TTOO
66
DELISTED
T2 Biosystems, Inc
TTOO
$1.16M 0.47%
+30
New +$1.14M
ANGO icon
67
AngioDynamics
ANGO
$651M
$1.13M 0.45%
+50,842
New +$1.04M
AKRX
68
CALL
DELISTED
Akorn Inc
AKRX
$1.13M 0.45%
+67,900
New +$1.04M
RCKT icon
69
Rocket Pharmaceuticals
RCKT
$397M
$1.01M 0.4%
51,459
-20,000
-28% -$378K
CLLS
70
Cellectis
CLLS
$278M
$990K 0.4%
+35,000
New +$1.04M
VKTX icon
71
PUT
Viking Therapeutics
VKTX
$4.02B
$949K 0.38%
+100,000
New +$665K
BSX icon
72
Boston Scientific
BSX
$73.1B
$818K 0.33%
25,000
-62,500
-71% -$1.89M
BLUE
73
DELISTED
bluebird bio
BLUE
$785K 0.31%
+386
New +$880K
FOLD
74
CALL
DELISTED
Amicus Therapeutics
FOLD
$781K 0.31%
+50,000
New +$756K
MOTS
75
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$719K 0.29%
333
– –
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SR
Swiss Re Zurich, Switzerland $16.4M AUM
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return

Pura Vida Investments's Q2 2018 Portfolio in Review

As of Q2 2018, Pura Vida Investments held 128 positions worth $250M, up 47% from $169M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Pura Vida Investments deployed $54.1M of net new capital in Q2 2018, opening 62 new positions and adding to 6 existing holdings. Its largest new stake was Inspire Medical Systems: 200,280 shares worth $7.14M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 52% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Merck, an estimated $4.14M trimmed.

  • Pura Vida Investments's largest Q2 2018 buy was Inspire Medical Systems: 200,280 shares worth $7.14M.
  • Pura Vida Investments added most to Allergan plc in Q2 2018, an estimated $1.61M increase.
  • Pura Vida Investments's biggest Q2 2018 reduction was Merck, cutting an estimated $4.14M.
  • Pura Vida Investments fully exited Abbott in Q2 2018, selling an estimated $3.63M.
  • Pura Vida Investments's ten largest holdings make up 37% of its $250M portfolio in Q2 2018.
  • Pura Vida Investments opened 62 new positions and closed 36 in Q2 2018.
  • Pura Vida Investments's portfolio value rose 47% quarter-over-quarter to $250M.

Based on Pura Vida Investments's 13F filing for Q2 2018, filed 14 Aug 2018.